JP2016510758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510758A5 JP2016510758A5 JP2015561682A JP2015561682A JP2016510758A5 JP 2016510758 A5 JP2016510758 A5 JP 2016510758A5 JP 2015561682 A JP2015561682 A JP 2015561682A JP 2015561682 A JP2015561682 A JP 2015561682A JP 2016510758 A5 JP2016510758 A5 JP 2016510758A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 CH 2 OH Chemical group 0.000 claims 58
- 150000001875 compounds Chemical class 0.000 claims 54
- 150000003839 salts Chemical class 0.000 claims 47
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000000335 thiazolyl group Chemical group 0.000 claims 9
- 125000005309 thioalkoxy group Chemical group 0.000 claims 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 claims 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229940125810 compound 20 Drugs 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- AHSUGOLUVUBUCR-XPIZARPCSA-N (1r,2r,6r)-2-[2-fluoro-5-[(3-methoxy-1,7-naphthyridin-8-yl)amino]phenyl]-2-methyl-5-oxa-3-azabicyclo[4.1.0]hept-3-en-4-amine Chemical compound N1=C(N)O[C@@H]2C[C@@H]2[C@]1(C)C1=CC(NC=2C3=NC=C(C=C3C=CN=2)OC)=CC=C1F AHSUGOLUVUBUCR-XPIZARPCSA-N 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- QFVRLYRYKCLRMD-UHFFFAOYSA-N cyclodecane-1,6-diol Chemical compound OC1CCCCC(O)CCCC1 QFVRLYRYKCLRMD-UHFFFAOYSA-N 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- INIRAFGCTHHCSF-UCMVZMLTSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-chlorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(Cl)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 INIRAFGCTHHCSF-UCMVZMLTSA-N 0.000 claims 1
- PZRUBQJUGSTHNP-IOHHAYIISA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-chlorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(Cl)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(C#N)C=N1 PZRUBQJUGSTHNP-IOHHAYIISA-N 0.000 claims 1
- XYFKLLZZEBOPKP-CJAGKMTESA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluoro-5-methylphenyl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound C=1C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C(F)C(C)=CC=1NC(=O)C1=NC=C(C#N)C=C1Cl XYFKLLZZEBOPKP-CJAGKMTESA-N 0.000 claims 1
- IHAUPMSNDMWWEF-KUUHDYPXSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluoro-5-methylphenyl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound C=1C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C(F)C(C)=CC=1NC(=O)C1=NC=C(C#N)C=C1C IHAUPMSNDMWWEF-KUUHDYPXSA-N 0.000 claims 1
- DHNSWMZPTCJXNN-CRPGXEFLSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=NC=C(Cl)C=C1Cl DHNSWMZPTCJXNN-CRPGXEFLSA-N 0.000 claims 1
- MVYKQTMWKRGHMH-GEDNVKPRSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=NC=C(C#N)C=C1Cl MVYKQTMWKRGHMH-GEDNVKPRSA-N 0.000 claims 1
- SGBYWDPTHVLPAE-GEDNVKPRSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C1 SGBYWDPTHVLPAE-GEDNVKPRSA-N 0.000 claims 1
- AZQBTXGCOVMMKB-KBARZSOFSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-(difluoromethoxy)-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(OC(F)F)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C1 AZQBTXGCOVMMKB-KBARZSOFSA-N 0.000 claims 1
- KLDGVZBFMGQONH-UCMVZMLTSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-bromopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(Br)C=N1 KLDGVZBFMGQONH-UCMVZMLTSA-N 0.000 claims 1
- YIUIJXBYTVHAJS-BBEJJTJUSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-chloro-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(Cl)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C1 YIUIJXBYTVHAJS-BBEJJTJUSA-N 0.000 claims 1
- RQUKXRXQXUNQGZ-UCMVZMLTSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 RQUKXRXQXUNQGZ-UCMVZMLTSA-N 0.000 claims 1
- GJUTYYBPDFWHKP-XBHMSOGKSA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CC=C(F)C([C@@]2([C@H]3C[C@H]3OC(N)=N2)C(F)F)=C1 GJUTYYBPDFWHKP-XBHMSOGKSA-N 0.000 claims 1
- UTTKUJQSCLBQAY-IOHHAYIISA-N n-[3-[(1r,2s,6r)-4-amino-2-(difluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(C(F)F)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(C#N)C=N1 UTTKUJQSCLBQAY-IOHHAYIISA-N 0.000 claims 1
- VLKWQZOQIHLUFL-YYFZDKIDSA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-chlorophenyl]-5-cyano-3-methylpyridine-2-carboxamide Chemical compound CC1=CC(C#N)=CN=C1C(=O)NC1=CC=C(Cl)C([C@]2(CF)[C@H]3C[C@H]3OC(N)=N2)=C1 VLKWQZOQIHLUFL-YYFZDKIDSA-N 0.000 claims 1
- WWKJHKHHTSVQED-UCMVZMLTSA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3,5-dichloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(CF)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=NC=C(Cl)C=C1Cl WWKJHKHHTSVQED-UCMVZMLTSA-N 0.000 claims 1
- XZUNYCSAJCRTCT-IOHHAYIISA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3-chloro-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(CF)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=NC=C(C#N)C=C1Cl XZUNYCSAJCRTCT-IOHHAYIISA-N 0.000 claims 1
- AKQCEODAEGEBAE-IOHHAYIISA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-3-chloro-5-methoxypyridine-2-carboxamide Chemical compound ClC1=CC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@]2(CF)[C@H]3C[C@H]3OC(N)=N2)=C1 AKQCEODAEGEBAE-IOHHAYIISA-N 0.000 claims 1
- QRSZQDAJIBKJOD-WBHUJUFNSA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(CF)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 QRSZQDAJIBKJOD-WBHUJUFNSA-N 0.000 claims 1
- DXWNBZXVWQVXCJ-URKNILKWSA-N n-[3-[(1r,2s,6r)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]2(CF)N=C(O[C@@H]3C[C@@H]32)N)=CC=1NC(=O)C1=CC=C(C#N)C=N1 DXWNBZXVWQVXCJ-URKNILKWSA-N 0.000 claims 1
- UIOZLTMFHBMGQX-MPSXMAJESA-N n-[3-[(1s,2r,6s)-4-amino-2-(fluoromethyl)-5-oxa-3-azabicyclo[4.1.0]hept-3-en-2-yl]-2,4-difluorophenyl]-5-methoxypyridine-2-carboxamide Chemical compound N1=CC(OC)=CC=C1C(=O)NC1=CC=C(F)C([C@@]2(CF)[C@@H]3C[C@@H]3OC(N)=N2)=C1F UIOZLTMFHBMGQX-MPSXMAJESA-N 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000007505 plaque formation Effects 0.000 claims 1
- 229960005206 pyrazinamide Drugs 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 CC(C)=CC=*(C(Nc(cc1)cc([C@@]2(CF)N=C(N)O[C@]3[C@]2C3)c1F)=*)N=C Chemical compound CC(C)=CC=*(C(Nc(cc1)cc([C@@]2(CF)N=C(N)O[C@]3[C@]2C3)c1F)=*)N=C 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775380P | 2013-03-08 | 2013-03-08 | |
| US61/775,380 | 2013-03-08 | ||
| US201461939580P | 2014-02-13 | 2014-02-13 | |
| US61/939,580 | 2014-02-13 | ||
| PCT/US2014/021412 WO2014138484A1 (en) | 2013-03-08 | 2014-03-06 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510758A JP2016510758A (ja) | 2016-04-11 |
| JP2016510758A5 true JP2016510758A5 (https=) | 2017-04-06 |
| JP6374889B2 JP6374889B2 (ja) | 2018-08-15 |
Family
ID=50478936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561682A Active JP6374889B2 (ja) | 2013-03-08 | 2014-03-06 | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9085576B2 (https=) |
| EP (1) | EP2964644B1 (https=) |
| JP (1) | JP6374889B2 (https=) |
| KR (1) | KR20150124985A (https=) |
| CN (1) | CN105164121A (https=) |
| AP (1) | AP2015008716A0 (https=) |
| AU (1) | AU2014225604B2 (https=) |
| BR (1) | BR112015021336A2 (https=) |
| CA (1) | CA2903215C (https=) |
| CL (1) | CL2015002516A1 (https=) |
| CR (1) | CR20150519A (https=) |
| EA (1) | EA201591614A1 (https=) |
| HK (1) | HK1217486A1 (https=) |
| IL (1) | IL240829A0 (https=) |
| MX (1) | MX374512B (https=) |
| PE (1) | PE20151794A1 (https=) |
| PH (1) | PH12015502001A1 (https=) |
| SG (1) | SG11201507196WA (https=) |
| TN (1) | TN2015000382A1 (https=) |
| TW (1) | TW201446760A (https=) |
| UY (1) | UY35377A (https=) |
| WO (1) | WO2014138484A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| MX2012006491A (es) | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| MX374512B (es) * | 2013-03-08 | 2025-03-06 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso. |
| SG10201707504VA (en) | 2013-03-13 | 2017-10-30 | Takeda Pharmaceuticals Co | Guanidinobenzoic acid ester compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
| US9868738B2 (en) * | 2014-09-19 | 2018-01-16 | Merck Sharp & Dohme Corp. | Diazine-fused amidines as BACE inhibitors, compositions, and their use |
| WO2016118404A1 (en) * | 2015-01-20 | 2016-07-28 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use |
| AR104555A1 (es) | 2015-05-07 | 2017-07-26 | Bristol Myers Squibb Co | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg |
| TW201718514A (zh) * | 2015-08-07 | 2017-06-01 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經２－（雜）芳基取代之稠合雜環衍生物 |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3165093A1 (en) | 2015-11-05 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) * | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) * | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN106432071B (zh) * | 2016-09-05 | 2019-04-02 | 河北正朗制药有限公司 | 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用 |
| EP3523279A1 (en) | 2016-10-10 | 2019-08-14 | Bristol-Myers Squibb Company | Tricyclic sulfones as ror gamma modulators |
| AU2017376441B2 (en) * | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047290A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| MX394391B (es) | 2016-12-15 | 2025-03-24 | Amgen Inc | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. |
| EP3555085B1 (en) | 2016-12-15 | 2020-12-02 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047288A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| SMT202500157T1 (it) | 2018-03-30 | 2025-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| AU2019258575A1 (en) | 2018-04-27 | 2020-10-29 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| CN109430267A (zh) * | 2018-10-24 | 2019-03-08 | 南京华安药业有限公司 | 一种肟草酮水悬浮剂 |
| CN110183392B (zh) * | 2019-06-14 | 2023-03-28 | 河北医科大学 | 一种3-取代苯基-4，5-二氢异噁唑衍生物的制备方法及其用途和中间体 |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| PE20221038A1 (es) | 2019-09-30 | 2022-06-17 | Incyte Corp | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN110885329B (zh) | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
| CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
| IL297887A (en) | 2020-05-05 | 2023-01-01 | Basf Se | History of isoxazoline concentrates and their use as herbicides |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| CN118852012A (zh) * | 2024-09-26 | 2024-10-29 | 山东国邦药业有限公司 | 一种高收率的二氟吡唑酸的合成方法 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| PL205294B1 (pl) | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| EP2335701B1 (en) | 2003-12-15 | 2012-07-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
| JP5383484B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | 環式基で置換されたアミノジヒドロチアジン誘導体 |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| PL2233474T3 (pl) | 2008-01-18 | 2015-12-31 | Eisai R&D Man Co Ltd | Skondensowana pochodna aminodihydrotiazyny |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| KR101324426B1 (ko) | 2008-06-13 | 2013-10-31 | 시오노기세야쿠 가부시키가이샤 | β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체 |
| CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
| WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| JPWO2011070781A1 (ja) | 2009-12-09 | 2013-04-22 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| MX2012006491A (es) * | 2009-12-11 | 2012-07-03 | Shionogi & Co | Derivados de oxazina. |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| US8673894B2 (en) * | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| CA2824097A1 (en) | 2011-01-12 | 2012-07-19 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| JP2014505689A (ja) | 2011-01-13 | 2014-03-06 | ノバルティス アーゲー | 代謝障害の処置用ｂａｃｅ−２阻害剤 |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
| US20140235626A1 (en) | 2011-04-26 | 2014-08-21 | Shionogi & Co., Ltd. | Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| AR086539A1 (es) | 2011-05-24 | 2014-01-08 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| AR086653A1 (es) | 2011-06-03 | 2014-01-15 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| CN103717592A (zh) | 2011-06-07 | 2014-04-09 | 霍夫曼-拉罗奇有限公司 | 作为bace1和/或bace2抑制剂的卤代-烷基-1,3噁嗪类 |
| CA2837797A1 (en) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
| US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| CN103874496A (zh) | 2011-08-22 | 2014-06-18 | 默沙东公司 | 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途 |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| US8476264B2 (en) | 2011-09-21 | 2013-07-02 | Hoffmann-La Roche Inc. | N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors |
| US9284284B2 (en) | 2011-10-13 | 2016-03-15 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
| US9133129B2 (en) | 2011-10-24 | 2015-09-15 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| MX354173B (es) | 2012-01-26 | 2018-02-16 | Hoffmann La Roche | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas. |
| EP2827857A4 (en) | 2012-03-20 | 2016-03-30 | Elan Pharm Inc | SPIROCYCLIC DIHYDRO-THIAZINE AND INHIBITORS OF BACE DIHYDRO-OXAZINE AND COMPOSITIONS AND USES THEREOF |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| CA2872181A1 (en) | 2012-06-26 | 2014-01-03 | F. Hoffmann-La Roche Ag | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| EP2897964A1 (en) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| WO2014059185A1 (en) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| EP2908824B1 (en) | 2012-10-17 | 2018-05-02 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9422277B2 (en) | 2012-10-17 | 2016-08-23 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| SI2912041T1 (sl) | 2012-10-26 | 2017-02-28 | Eli Lilly And Company | Derivati tetrahidropirolotiazina kot inhibitorji beta sekretaze (bace) |
| WO2014093190A1 (en) | 2012-12-14 | 2014-06-19 | Merck Sharp & Dohme Corp. | Bace inhibitors of iminothiadiazine dioxides |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9475784B2 (en) | 2012-12-19 | 2016-10-25 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production |
| EP2934539B1 (en) | 2012-12-20 | 2019-03-27 | Merck Sharp & Dohme Corp. | C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors |
| WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
| WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| MX374512B (es) | 2013-03-08 | 2025-03-06 | Amgen Inc | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso. |
| AU2014229010B2 (en) | 2013-03-15 | 2018-05-10 | Nano Composite Products, Inc. | Composite material used as a strain gauge |
| AU2014253275B2 (en) | 2013-04-11 | 2018-10-18 | F. Hoffmann-La Roche Ag | BACE1 inhibitors |
| SG11201508814SA (en) | 2013-04-26 | 2015-11-27 | Hoffmann La Roche | Synthesis of bace inhibitors |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
-
2014
- 2014-03-06 MX MX2015011618A patent/MX374512B/es active IP Right Grant
- 2014-03-06 HK HK16105452.2A patent/HK1217486A1/zh unknown
- 2014-03-06 AP AP2015008716A patent/AP2015008716A0/xx unknown
- 2014-03-06 EA EA201591614A patent/EA201591614A1/ru unknown
- 2014-03-06 CN CN201480013095.9A patent/CN105164121A/zh active Pending
- 2014-03-06 US US14/199,844 patent/US9085576B2/en active Active
- 2014-03-06 SG SG11201507196WA patent/SG11201507196WA/en unknown
- 2014-03-06 WO PCT/US2014/021412 patent/WO2014138484A1/en not_active Ceased
- 2014-03-06 AU AU2014225604A patent/AU2014225604B2/en active Active
- 2014-03-06 EP EP14717004.7A patent/EP2964644B1/en active Active
- 2014-03-06 KR KR1020157026887A patent/KR20150124985A/ko not_active Withdrawn
- 2014-03-06 BR BR112015021336A patent/BR112015021336A2/pt not_active IP Right Cessation
- 2014-03-06 JP JP2015561682A patent/JP6374889B2/ja active Active
- 2014-03-06 CA CA2903215A patent/CA2903215C/en active Active
- 2014-03-06 PE PE2015001879A patent/PE20151794A1/es not_active Application Discontinuation
- 2014-03-07 TW TW103108045A patent/TW201446760A/zh unknown
- 2014-03-10 UY UY0001035377A patent/UY35377A/es not_active Application Discontinuation
-
2015
- 2015-04-21 US US14/691,715 patent/US20150252011A1/en not_active Abandoned
- 2015-08-25 IL IL240829A patent/IL240829A0/en unknown
- 2015-08-31 TN TN2015000382A patent/TN2015000382A1/en unknown
- 2015-09-08 CL CL2015002516A patent/CL2015002516A1/es unknown
- 2015-09-08 PH PH12015502001A patent/PH12015502001A1/en unknown
- 2015-10-05 CR CR20150519A patent/CR20150519A/es unknown
- 2015-11-04 US US14/932,787 patent/US9611261B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510758A5 (https=) | ||
| JP2016511258A5 (https=) | ||
| RU2655914C2 (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP7290573B2 (ja) | 抗ウイルス剤としての融合インダゾールピリドン化合物 | |
| TWI712595B (zh) | 三環性螺化合物 | |
| AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| AU2011270798B2 (en) | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents | |
| ES2366082T3 (es) | Pirazolo 1,5-a piridinas y medicinas que las contienen. | |
| CN108602802A (zh) | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 | |
| JP2021503458A (ja) | 新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用 | |
| TW202229300A (zh) | 囊腫纖維化跨膜傳導調節蛋白之調節劑 | |
| AU2019217320A1 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| JP2016519165A5 (https=) | ||
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| JP2021512146A (ja) | キャップ依存性エンドヌクレアーゼ阻害剤 | |
| JP2020502092A5 (https=) | ||
| JP2017523223A5 (https=) | ||
| JP2016503785A5 (https=) | ||
| WO2017123991A1 (en) | Pyridazine derivatives as eaat2 activators | |
| JP2013525481A (ja) | ＰＫＣ−θインヒビターとして有用な４置換ピラゾロピリミジン | |
| JP2015502371A5 (https=) | ||
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| CA2787315A1 (en) | Pyrazolopyridine kinase inhibitors | |
| EP3724196A1 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| JP2014501772A (ja) | タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途 |